Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences (BUMS), Birjand, Iran
Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan
CNS Neurol Disord Drug Targets. 2020;19(5):334-343. doi: 10.2174/1871527319666200708130745.
Deposition of Amyloid-beta (Aβ) peptide in the brain is the leading source of the onset and progression of Alzheimer's Disease (AD). Recent studies have suggested that anti-amyloidogenic agents may be a suitable therapeutic strategy for AD. The current review was proposed to address the beneficial effects of cannabis-based drugs for the treatment of AD, focusing primarily on Aβ modifications. Keywords related to AD, Aβ, and cannabis-based on MeSH were identified and were searched in PubMed, Google Scholar, Scopus, Ovid-Medline, and Web of Science from inception until 15 March 2020. The full text of identified papers was obtained and assessed based on exclusion and inclusion criteria. The review is based on articles that have focused on AD and the amyloidogenic pathway. A total of 17 studies were identified based on the inclusion criteria; however, nine studies qualified for this systematic review. The maximum and minimum cannabis dosages, mostly CBD and THC in animal studies, were 0.75 and 50 mg/kg, respectively. Cannabis (CBD and THC) was injected for 10 to 21 days. The findings of the 9 articles indicated that cannabis-based drugs might modulate Aβ modifications in several AD models. Our findings establish that cannabis-based drugs inhibited the progression of AD by modulating Aβ modifications.
淀粉样蛋白-β（Aβ）肽在大脑中的沉积是阿尔茨海默病（AD）发病和进展的主要原因。最近的研究表明，抗淀粉样蛋白生成药物可能是 AD 的一种合适的治疗策略。本综述旨在探讨基于大麻的药物治疗 AD 的有益作用，主要集中在 Aβ修饰上。确定了与 AD、Aβ 和基于 MeSH 的大麻相关的关键词，并在 PubMed、Google Scholar、Scopus、Ovid-Medline 和 Web of Science 中进行了搜索，从成立到 2020 年 3 月 15 日。根据排除和纳入标准，获得并评估了已确定论文的全文。本综述基于专注于 AD 和淀粉样蛋白形成途径的文章。根据纳入标准共确定了 17 项研究，但有 9 项研究符合本系统综述的标准。动物研究中最大和最小的大麻剂量，主要是 CBD 和 THC，分别为 0.75 和 50mg/kg。大麻（CBD 和 THC）注射 10 至 21 天。9 篇文章的结果表明，基于大麻的药物可能通过调节 Aβ 修饰来调节几种 AD 模型中的 Aβ 修饰。我们的研究结果表明，基于大麻的药物通过调节 Aβ 修饰来抑制 AD 的进展。
